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Abstract 
Chemerin is a chemoattractant factor for leukocytes involved in various 
inflammatory diseases and human cancers. This protein is acting through three G 
protein-coupled receptors: ChemR23, GPR1 and CCRL2.  
ChemR23 is the main receptor, present in immune cells and non-immune cells. 
Its main function is described as involving the migration of various leukocyte 
populations. GPR1 is expressed mainly in the central nervous system. It binds 
chemerin with high affinity but signals poorly, and its functional role is presently 
unclear. CCRL2 is a non-functional receptor expressed by immune cells and 
endothelial cells. Its proposed role is to concentrate chemerin and present the 
ligand to ChemR23-expressing cells.  
In this work, we intended to contribute to the understanding of the role of CCRL2 
and ChemR23 in tumor development using, for each receptor, genetically deficient 
mouse lines and tumor cell line grafts. Using B16 melanoma and Lewis lung 
carcinoma cell lines as models, we did not observe differences in tumor growth and 
recruitment of leukocyte populations to the experimental tumors in ChemR23-
deficient mice, suggesting that ChemR23 does not affect the tumor development. 
In the CCRL2 absence, we observed a significant decrease of tumor growth, 
suggesting a pro-tumoral effect of CCRL2. The immune cell recruitment and the 
blood chemerin levels were similar in CCRL2-deficient and wild-type mice. The 
proliferative and apoptotic cells were analyzed by fluorescence microscopy, in 
tumors from wild-type and CCRL2-deficient mice. The tumor cells proliferated 
equally in the two groups. However, we observed a higher proportion of apoptotic 
cells and necrotic areas in the absence of CCRL2. As CCRL2 is present in 
endothelial cells, we tested whether the increase of apoptotic cells could be 
explained by an alteration of angiogenesis in the absence of the receptor. We 
analyzed for this purpose the expression of factors known to regulate angiogenesis 
in tumors from CCRL2+/+ and CCRL2-/- mice. The results showed that CCRL2 
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invalidation affects the expression of thrombospondin 1 (TSP1), vascular 
endothelial growth factor A (VEGFA) and fibroblast growth factor 2 (FGF2).  
Although further experiments will be necessary to confirm and extent our 
observations, we have shown in this work that CCRL2 contributes to tumor 
angiogenesis and support therefore tumor progression, preventing necrosis and 
apoptosis of tumor cells. 
 
 
Key-words 
Chemerin; CCRL2; ChemR23; angiogenesis; apoptosis; cancer  
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Resumo 
A chemerin foi identificada no nosso laboratório como sendo uma proteína 
quimioatraente de células imunitárias. Vários estudos mostraram que esta proteína 
pode apresentar um efeito inibitório ou promotor de tumores, dependendo do tipo 
de cancro. Se por um lado, foi mostrado um efeito anti-tumoral em cancros do 
pulmão, próstata e melanoma, onde a concentração de chemerin está diminuída 
em pacientes doentes, outro estudo mostra um aumento de chemerin em 
pacientes com diferentes tipos de cancros gástricos, e por isso, apresenta um 
efeito pro-tumoral.  
A chemerin é encodada pelo gene tazarotene-induced 2, e é expressa 
principalmente no fígado e tecido adiposo, mas também na glândula adrenal, 
pâncreas, pulmões e pele. O seu precursor, prochemerin, está biologicamente 
inativo e requer uma clivagem proteolítica para se ativar e tornar-se chemerin.  
A chemerin tem a capacidade de se ligar a três receptores acoplados a 
proteína G: ChemR23, GPR1 e CCRL2.  
ChemR23 é descrito como o principal receptor da chemerin e é expresso 
em células do sistema imunitário como macrófagos e células natural killer, mas 
também em células não hematopoiéticas, como adipócitos e células endoteliais. A 
ligação da chemerin ao receptor ChemR23 promove a internalização do receptor, 
a mobilização de cálcio e a quimiotaxia de células imunitárias que expressam este 
receptor. Alguns estudos mostraram funções do sistema chemerin/ChemR23 a 
nível inflamatório, que pode influenciar a migração das células endoteliais, 
apresentando um efeito anti-inflamatório. 
GPR1 é expresso em células do sistema nervoso, placenta, pele, entre 
outros, mas não em células do sistema imunitário. Este receptor liga-se com 
elevada afinidade a chemerin, ocorrendo a internalização do receptor. Porém, não 
foi detetada nenhuma sinalização intracelular. Desta forma, a função deste 
receptor e a sua interação com a chemerin continua por esclarecer.  
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CCRL2 encontra-se presente em macrófagos, células dendríticas e em 
células endoteliais. Este receptor liga-se com elevada afinidade a chemerin, mas 
não ocorre sinalização intracelular nem a internalização do receptor, sugerindo 
que este receptor é não funcional. Foi mostrado a hipótese que CCRL2 apresenta 
a chemerin ao receptor ChemR23, e que tem a capacidade de promover a 
migração de células dendríticas via a chemerin.  
Com este projeto, pretendemos compreender o papel da chemerin e de 
dois receptores, CCRL2 e ChemR23, no desenvolvimento tumoral. Para tal, 
usamos ratinhos deficientes para cada um dos receptores que recebem 
xenógrafos de linhas celulares tumorais. Este modelo de tumorigenése permitirá 
analisar quais os processos tumorais afetados por estes receptores, tal como, a 
proliferação e apoptose de células tumorais, o recrutamento de populações de 
células imunitárias e a expressão de fatores angiogénicos.  
Para analisar o efeito da deficiência de ChemR23 no desenvolvimento 
tumoral, foi injectado um milhão de células provenientes de melanoma (linha B16) 
nos flancos de ratinhos wild-type e knock-out para ChemR23. Os tumores foram 
medidos diariamente até dez dias após a implantação.  
0Os resultados mostram que os tumores em ratinhos wild-type e knock-out para 
ChemR23 surgem de forma igual e que desenvolvem de igual forma. Isto sugere 
que ChemR23 não está envolvido no desenvolvimento tumoral, neste modelo 
tumoral. Observamos, igualmente, a influência de ChemR23 na migração de 
células imunitárias atá ao site tumoral, via citometria de fluxo. Os resultados 
mostraram que a ausência de ChemR23 não afetou a migração de células 
imunitárias, no geral, nem as diversas subpopulações analisadas, sugerindo que 
este receptor não influencia a migração das células imunitárias em resposta a um 
tumor. Estes resultados são consistentes com os resultados observados no 
crescimento tumoral. 
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Para saber se CCRL2 está envolvido no controlo do desenvolvimento tumoral, 
um milhão de células B16 foram injetadas nos flancos em ratinhos wild-type e 
knock-out para CCRL2, observando o desenvolvimento tumoral ao longo de vários 
dias. Os tumores dos ratinhos wild-type e knock-out desenvolvem-se ao mesmo 
tempo mas nos ratinhos knock-out os tumores são menores. Estes resultados 
sugerem que CCRL2 tem um efeito pró-tumoral neste modelo tumoral. Este efeito 
foi confirmado com outra linha de células tumorais provenientes de carcinoma 
pulmonar de Lewis, que apresentou resultados semelhantes.  
Para perceber o efeito de CCRL2 na migração de células imunitárias, 
analisamos o recrutamento de células imunitárias em tumores de células B16, por 
citometria de fluxo. As populações de células imunitárias foram analisadas 
diversos dias após a implantação tumoral (3, 6 e 10 dias). Os resultados das 
diferentes análises sugerem que tanto a população total de células imunitárias 
como as diversas subpopulações não são afetadas pela ausência de CCRL2. 
Estes resultados foram confirmados por microscopia de fluorescência, onde se 
marcou células imunitárias com anticorpos fluorescentes em cortes de tumores. 
Os resultados mostraram a mesma proporção de células imunitárias, bem como a 
mesma distribuição em ambos os grupos de ratinhos. Confirmamos que CCRL2 
não afeta o recrutamento de células imunitárias ao realizar a mesma experiência 
com tumores de células LLC, obtendo assim os mesmos resultados.  
De forma a perceber o efeito de CCRL2 no desenvolvimento tumoral e a sua 
influência na migração de células imunitárias, determinamos as consequências do 
défice de CCRL2 nas concentrações plasmáticas totais de chemerin. Amostras de 
sangue de ratinhos wild-type e knock-out foram analisadas por ELISA. Os 
resultados mostraram que a concentração nos dois grupos é igual, sugerindo que 
a concentração total de chemerin não é afetada por este receptor. 
Via um teste aequorin e purificação por HPLC (high pressure liquid 
chromatography), foi analisada a concentração plasmática de chemerin bioativa 
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nos dois grupos de ratinhos, e observou-se que a concentração era similar nos 
dois grupos.  
A concentração total de chemerin também foi analisada, por ELISA, após a 
implantação de células tumorais. Os resultados mostraram um aumento da 
concentração de chemerin após a implantação tumoral em ambos os grupos de 
ratinhos. Porém, não foram observadas diferenças da concentração plasmáticas 
na ausência de CCRL2.  
Estes resultados sugerem que o efeito observado em CCRL2 não pode ser 
explicado pela concentração de chemerin plasmática total e ativa, visto que esta 
não é alterada estas experiências mostram que a diminuição de tamanho de 
tumores em ratinhos knock-outs não se deve a concentração de chemerin nem a 
proporções de células imunitárias recrutadas para o site tumoral.  
Por estar presente em células endoteliais, tentamos perceber a influência 
de CCRL2 na neo-angiogénese tumoral e as consequências na sobrevivência 
celular e proliferação tumoral.  
A proliferação e a apoptose celular foram analisadas por 
imunofluorescência, em tumores de células B16, a três e a seis dias de 
desenvolvimento tumoral. Ao analisar a colocalização de células em proliferação, 
observamos semelhante proliferação em ratinhos wild-type e knock-out, nos dois 
dias, sem aparentarem diferenças, sugerindo que CCRL2 não afeta este processo.  
Analisamos a apoptose celular em tumores de células LLC a dez dias de 
desenvolvimento tumoral, por imunofluorescência. Observamos um aumento de 
células apoptóticas, na ausência de CCRL2, quando comparado ao grupo wild-
type. Observamos também que as regiões apoptóticas estão à periferia das 
regiões necróticas, que também estão aumentadas, comparando com o grupo 
wild-type. Estes resultados mostram que CCRL2 parece ter um efeito nos 
processos de apoptose e na necrose deste modelo tumoral.  
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Estes processos estão correlacionados com a angiogénese tumoral. Desta 
forma, para entender a interação com CCRL2, observou-se a expressão de fatores 
angiogénicos em tumores de células LLC a dez dias de desenvolvimento tumoral, 
por PCR quantitativa. 
Os resultados mostraram que, na ausência de CCRL2 a expressão de 
trombospondina-1, VEGFA e FGF2 estão aumentados comparando com o grupo 
controlo. Estes resultados preliminares sugerem que CCRL2 pode ter uma 
significante influência no controlo da angiogénese tumoral, moldada pela 
expressão de fatores angiogénicos, e consequentemente, alterando a apoptose 
tumoral. 
  Com este trabalho, é possível concluir que ChemR23, receptor principal da 
chemerin, não influencia o desenvolvimento tumoral nem o recrutamento 
imunitário, não estando por isso implicado nos efeitos antitumorais da chemerin, 
neste modelo tumoral. Por outro lado, CCRL2, um receptor não-funcional, 
apresenta um efeito pró-tumoral no mesmo modelo experimental. Este efeito deve-
se a sua influência na angiogénese, que poderá vir a ser explicado pela sua 
implicação na expressão de trombospondina-1 ou na migração de células 
endoteliais.  
Como perspetiva, pretendemos compreender melhor o papel de CCRL2 a 
nível da angiogénese. Com isto, analisaremos a expressão de outros fatores 
angiogénicos, a correlação com o TSP1, VEGFA e o FGF2, bem como na 
influência na migração de células endoteliais para o site tumoral.  
 
Palavras-chave: 
Chemerin; CCRL2; ChemR23; angiogenése; apoptose; cancro. 
  
Role of chemerin and its receptors in mouse models of tumorigenesis 
 
 
 
 
Bárbara Sofia Marques da Silva 
x 
 
Index 
Agradecimentos i 
Acknowledgments ii 
Abstract iii 
Key-words iv 
Resumo v 
Palavras-chave ix 
Abbreviations xiii 
1. INTRODUCTION 1 
1.1 CANCER  1 
1.2 TUMOR MICROENVIRONMENT 5 
1.3 CHEMERIN 8 
 1.3.1 CHEMR23 9 
 1.3.2 GPR1 11 
 1.3.3 CCRL2 11 
2. AIMS OF PROJECT 13 
3. MATERIALS AND METHODS 14 
3.1 ANIMALS 14 
3.2 TUMOR CELL LINES 14 
3.3 GRAFTING OF TUMOR CELL LINES 15 
3.4 TUMOR DIGESTION 16 
3.5 FLOW CYTOMETRY ANALYSIS 16 
3.6 IMMUNOFLUORESCENCE MICROSCOPY 19 
3.7 HEMATOXYLIN/EOSIN STAINING 20 
3.8 ELISA 21 
3.9 RT-QPCR 22 
3.10 HPLC 25 
3.11 STATISTICAL ANALYSES 
 
27 
Role of chemerin and its receptors in mouse models of tumorigenesis 
 
 
 
 
Bárbara Sofia Marques da Silva 
xi 
 
4. RESULTS 29 
4.1 CHEMR23 IS NOT INVOLVED IN THE CONTROL OF B16 
TUMOR DEVELOPMENT 
29 
4.2 THE ABSENCE OF CCRL2 LEADS TO A DECREASE OF 
TUMOR GROWTH 
32 
4.3 THE PLASMA CHEMERIN CONCENTRATION IS NOT 
ALTERED IN CCRL2-DEFICIENT MICE 
34 
4.4 CCRL2 DOES NOT AFFECT THE IMMUNE CELL 
RECRUITMENT TO B16 AND LLC TUMORS 
35 
4.5 CCRL2 DOES NOT INFLUENCE THE PROLIFERATION OF 
TUMOR CELLS, BUT AFFECTS THEIR SURVIVAL 
41 
4.6 THE EXPRESSION OF ANGIOGENIC AND INFLAMMATORY 
FACTORS IS MODIFIED IN CCRL2-DEFICIENT MICE 
45 
5. DISCUSSION 47 
6. CONCLUSION 51 
7. BIBLIOGRAPHY 52 
 
  
Role of chemerin and its receptors in mouse models of tumorigenesis 
 
 
 
 
Bárbara Sofia Marques da Silva 
xii 
 
Index of tables and figures 
Table 3.1 Primers of angiogenic and inflammatory factors used to 
quantitative PCR 
24 
  
Figure 1.1 Hallmarks of Cancer 3 
Figure 1.2 Mechanisms of Chemerin Cleavage 9 
Figure 3.1 Flow Cytometry 17 
Figure 4.1 ChemR23+/+ (n=5) and ChemR23-/- (n=5) mice develop tumor 
in a similar way 
30 
Figure 4.2 The immune cell recruitment to B16 tumors is not affected by 
ChemR23 
31 
Figure 4.3 B16 and LLC tumors develop more slowly in CCRL2-deficient 
mice 
33 
Figure 4.4 The circulating levels of chemerin are not altered in CCRL2 
knock-out mice. 
35 
Figure 4.5 The immune cell recruitment to B16 tumors is not affected by 
CCRL2, at day 10 of tumor growth. 
36 
Figure 4.6 The immune cell recruitment to tumors is not affected by 
CCRL2, at day 3 (top panels) and day 6 (bottom panels) of tumor growth. 
38 
Figure 4.7 CCRL2+/+ and CCRL2-/- mice present similar proportion and 
location of immune cells in tumors. 
39 
Figure 4.8 The immune cell recruitment is not affected by CCRL2 in LLC 
tumors. 
40 
Figure 4.9 B16 tumors from CCRL2+/+ and CCRL2-/- mice display a 
similar proportion of proliferating cells. 
42 
Figure 4.10 In the absence of CCRL2, tumors present an increase in 
necrotic areas and apoptotic cells. 
44 
Figure 4.11 CCRL2 invalidation affects the expression of 
thrombospondin-1, VEGFA and FGF2 in LLC tumors. 
46 
Role of chemerin and its receptors in mouse models of tumorigenesis 
 
 
 
 
Bárbara Sofia Marques da Silva 
xiii 
 
Abbreviations 
7-AAD: 7-aminoactinomycin 
APCs: antigen presenting cells 
APC: allophycocyanin 
BSA: bovine serum albumin 
CCL2: Chemokine (C-C Motif) Ligand 2 
CCRL2: C-C Chemokine Receptor Like 2 
CMKLR1: chemokine-like receptor 1 
ChemR23: chemerin receptor 23 
CHO: Chinese hamster ovary 
CXCL1: Chemokine (C-X-C Motif) Ligand 1 
CXCL2: Chemokine (C-X-C Motif) Ligand 1 
Cy: Cyanine 
DC: dendritic cells 
DNA: deoxyribonucleid acid 
EC: endothelial cells 
EDTA: Ethylenediamine tetraacetic acid 
FBS: fetal bovine serum 
FITC: fluorescein isothiocyanate 
FGF2: Fibroblast Growth Factor 2 
GAPDH: Glyceraldehyde-3-Phosphate Dehydrogenase 
Role of chemerin and its receptors in mouse models of tumorigenesis 
 
 
 
 
Bárbara Sofia Marques da Silva 
xiv 
 
GPCR: G protein-coupled receptor 
HIF1 alpha: hypoxia induced factor subunit 1 alpha 
HPLC: high pressure liquid chromatography 
IL1beta: Interleukin 1 beta 
IL6: Interleukin 6 
IL10: Interleukin 10 
LLC: Lewis lung carcinoma 
MDSC: myeloid derived supressor cells 
MMP7: matrix metalloprotease 7 
MMP9: matrix metalloprotease 9 
MMP10: matrix metalloprotease 10 
NK cells: natural killer cells 
Nm: nanomolar 
PBS: phosphate buffered saline 
pDC: plasmacytoid dendritic cells 
PFA: paraformaldehyde 
PE: R-phycoerythrin 
PerCP: Peridinine Clorophyll Protein Complex 
RARRES2: retinoid acid receptor responder protein 2 
RT: room temperature 
RT-qPCR: reverse transcriptase quantitative polymerase chain reaction  
Role of chemerin and its receptors in mouse models of tumorigenesis 
 
 
 
 
Bárbara Sofia Marques da Silva 
xv 
 
Streptavidin-HRP: streptavidin Horseradish peroxidase 
TGF-beta: Transforming Growth Factor, Beta 1 
TIG2: tazarotene-induced gene 2 
TNFalpha: Tumor necrosis factor alpha 
TSP1: thrombospondin 1 
VEGFA: Vascular Endothelial Growth Factor A
Role of chemerin and its receptors in mouse models of tumorigenesis 
 
 
 
 
Bárbara Sofia Marques da Silva 
1 
 
1. INTRODUCTION 
1.1 CANCER 
Presently, cancer is a major problem in public health throughout the world, 
accounting for over a quarter of all deaths in developed countries (Macharet et al., 
2015). 
In 2012, cancer had an incidence of 14.1 million new cases and killed about 
8.2 million patients worldwide. In Portugal, the values are also high, with an 
incidence of 426 patients for 100,000 individuals, and cancer kills about one third 
of these patients. Globally, 40% of those cases are due to lung, breast, colorectal 
and stomach cancers, the most common being lung cancer in men and breast 
cancer in women (Direção-Geral de Saúde, 2014) (World Cancer Factsheet, 
2014).  
A malignant tumor is the result of the accumulation of DNA mutations in a 
cell or in a population of identical cells - a clone - in determinant genes, resulting in 
the transformation of a normal cell to a tumor cell. These mutations lead to the loss 
of the normal function of the gene, or rather to its uncontrolled activity, promoting 
aberrant or uncontrolled cell growth, decreasing apoptotic cell death, enhancing 
angiogenesis and cell migration and driving ultimately the development of distant 
metastases (Brennan, 2012). 
There are many differences amongst the various types of cancer, but there 
is a set of common properties that are shared by all types, which are defined as the 
“hallmarks of cancer”. These hallmarks include sustained proliferative signaling, 
evasion from growth suppressors, escape from apoptosis, tissue invasion and 
metastasis, unlimited replicative potential, sustained angiogenesis, evasion of 
immune surveillance, deregulated cellular energetics, genomic instability, and 
tumor promoting inflammation (Macharet et al., 2015). 
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The main characteristic of a tumor cells is their ability to proliferate in an 
uncontrolled manner. In tumor cells, the signaling pathways leading to proliferation 
are often activated constitutively, while the cells have gained the ability to escape 
from the effects of proliferative suppressors, such as TGF-. This supports a 
permanent and excessive proliferation, resulting in genomic instability in the cell, 
thereby increasing the number of acquired mutations and, consequently, 
accelerating the tumor progression. In combination with excessive cell proliferation, 
there is also an excessive cell growth, due to the ability of tumor cells to escape 
growth suppressors, such as p53 and the retinoblastoma protein (pRb). The cancer 
cells also gain a high capacity to resist cell death by evasion from apoptotic 
inducers and the upregulation of telomerase, which makes them immortal 
(Broertjes, 2015). 
The immune system has been viewed as a promising target for anticancer 
therapy, as it has the potential to recognize cancer cells and kill them through the 
activation of various effector pathways. However, several studies have shown that 
inflammation plays a dual role in tumor development. Immune cells, through 
chronic inflammation, have the ability to produce molecules that promote tumor cell 
proliferation, resistance to cell death, angiogenesis, genetic instability and 
metastasis. In addition, some cancer cells have also gained the ability to escape 
from the immune detection system, which represents an obvious selective 
advantage during tumor progression (Broertjes, 2015).  
The uncontrolled proliferation of tumor cell induces a high pressure in the 
tissue, which prevents the adequate supply of oxygen and nutrients to tumor cells. 
In response to hypoxic conditions that result from the relative lack of blood supply, 
the cells change their metabolic program, favoring aerobic glycolysis over oxidative 
phosphorylation, and leading to an energetic dysregulation in the cell. To 
counteract the state of hypoxia, tumor cells induce the production of new blood 
vessels irrigating the tumor, by secreting angiogenic factors such as VEGF and 
FGFs (Broertjes, 2015). 
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The vascularization of a tumor also allows the tumor cells to metastasize. 
The metastatic process begins by an invasion of surrounding tissue by the tumor 
cells, followed by the intravasation of cells into the bloodstream and / or the 
lymphatic vessels following their passage through the endothelial wall, and finally 
the extravasation of cancer cells to a distant tissue or organ away from the primary 
tumor. The biggest challenge for metastatic tumor cells is survive in the new 
microenvironment they face at the metastatic sites (Broertjes, 2015).  
 
 
Figure 1.1 Hallmarks of cancer. To become tumoral, a normal cell is the target of 
several molecular events, which result in sustained proliferative signaling, evasion 
of growth suppressors, escape from apoptosis, tissue invasion and metastasis, etc. 
(Adapted from Hanahan et al., 2011) 
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The susceptibility to developing cancer results from genetic and epigenetic 
factors as well as environmental factors such as exposure to external carcinogens. 
Genetic factors can be inherited for a small fraction. The frequency of 
genetically inherited cancers is indeed relatively low. Most genetic alterations are 
somatic and accumulate in cells during development and thereafter. Genes that 
are frequently mutated in cancer can be divided in two groups: the proto-
oncogenes, where the mutations activate the gene product and thereby contributes 
to the tumor development; and suppressor tumor genes, in which the mutations 
inhibit the gene function, thereby affecting its antitumoral properties such as 
induction of apoptosis and inhibition of proliferation. Some of the most common 
mutations found in human tumors affect genes such as TP53, PIK3CA3, PTEN, 
APC, VHL, KRAS, etc. (Macharet et al, 2015). 
Epigenetics has also an important role in cancer, because alteration of 
epigenetics marks can affect the function of DNA segments, independently of its 
sequence. The epigenetic alterations can occur as changes in DNA methylation, 
post-translational histone modifications, and in non-coding RNA or interference 
RNA (RNAi) that control the stability and translation of protein-encoding transcripts 
(Herceg, 2007). 
The external carcinogens can be environmental and divided in three groups: 
outdoor air pollutants (industrial polluents); indoor air pollutants (tobacco) and 
pollutants present in water, such as the arsenic (Broffeta et al., 2003). Thus, it is 
considered that cancer is a complex multifactorial disease (Brennan, 2012). 
To better understand the cancer development and plan a potential 
anticancer treatments, it is necessary to understand the early stages of a tumor 
and the interactions of the cancer cells with the tumor microenvironment.  
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1.2 TUMOR MICROENVIRONMENT 
Excessive proliferation prevents adequate supply of oxygen and nutrients to the 
tumor, inducing apoptosis and necrosis.  
To grow up and to sustain their excessive proliferation, tumor cells need to 
interact with their microenvironment and create a milieu favorable to the 
development of the tumor. This requires the building of an adequate blood supply, 
but also the control of the immune system, which may otherwise combat tumor 
cells and lead to their apoptotic or necrotic death.  
Tumor angiogenesis consists in the formation of new vessels from preexisting 
ones, in response to the production of angiogenic factors by tumor cells or the 
tumoral stroma. The tumor vasculature is characterized to be structurally and 
functionally chaotic, both in size and shape, with a discontinuous endothelium, 
extended basement membrane and aberrant pericyte coverage (Horssen et al., 
2006) (Stockmann et al., 2014). In the absence of angiogenesis, the growth of 
primary tumors is limited and metastases remain dormant. When tumoral cells 
undergo what is called an “angiogenic switch”, they become able to secrete 
angiogenic factors. These factors promote sprouting from neighboring blood 
vessels and the migration of endothelial cells toward the tumor (Horssen et al., 
2006).  
Aberrant cell proliferation also promotes the migration of leukocytes to the tumor 
site. The primary function of recruited cells from the innate immune system is to 
stop tumor progression. NK cells are the first immune population to detect tumor 
cells, and kill them by contact. (Finn, 2012) NK cells have two lytic mechanisms: 
(1) release of granzymes and perforin; (2) induction of apoptosis through the 
release of tumor necrosis factor alpha (TNFα). Dendritic cells and macrophages 
(APC) are resident cells in normal tissues, acting as sentinels probing the 
microenvironment and responding to stress signals. APCs have the capacity to 
recognize tumor cells through the detection of antigens resulting from genetic 
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mutations (Chimal-Ramirez et al., 2013). APCs secrete many inflammatory 
cytokines in the tumor site and present tumor antigens to T lymphocytes (T cells) 
and B lymphocytes (B cells) in the draining lymph nodes. APCs induce the clonal 
expansion of tumor antigen-specific T cells, and activate CD4+ helper and CD8+ 
cytotoxic T cells. CD4+ helper T cells have the capacity to produce inflammatory 
cytokines that increase the migration of leukocytes to the tumor site. CD8+ 
cytotoxic T cells recognize specifically the tumor cells and induce their apoptosis 
through the release of perforin and granzymes (Quail et al., 2013). APC also 
present tumor antigens to B cells, activating them. As CD4+ and CD8+ T cells, B 
cells belong to the adaptive immune system, and they produce specific antibodies 
to prevent tumor recurrence (Finn, 2012). 
Various mechanisms allow tumor cells to escape the immune system. Tumors 
can indeed recruit and modify the behavior of several immune cell populations, 
which will display anti-inflammatory functions. It includes myeloid-derived 
suppressor cells (MDSC), regulatory T cells (Treg) and M2 macrophages. The 
presence of these cells in the tumor microenvironment will in turn inhibit the host 
anti-tumoral immune response and promote instead tumor growth and 
neoangiogenesis. The anti-tumoral activity of CD4+ and CD8+ T cells can be 
regulated by anti-inflammatory cells such as regulatory T cells (Treg) and myeloid-
derived suppressor cells (MDSC). Treg cells have the capacity to produce 
immunosuppressive cytokines, kill directly conventional T cells, and inhibit the 
priming of these cells in lymphoid tissues (Gallimor et al., 2008). MDSCs have the 
ability to inhibit the function of CD4+ and CD8+ T cells by several mechanisms, 
including the inhibition of T cell proliferation in response to antigenic peptides and 
the loss of expression of TCR ζ chain (Watanabe et al., 2008). MDSCs also act on 
NK cells by suppressing their cytotoxic activity by the inhibition of IL2-mediated NK 
cell activation and the inhibition of perforin production (Liu et al., 2010).  
Although macrophages have an anti-tumoral role through their antigen-
presenting capability, a subset, the so-called M2 polarized macrophages, promote 
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instead tumor development. They are able to migrate to the hypoxic regions of 
tumors and induce angiogenesis, by the secretion of angiogenic factors such as 
VEGF and FGF2. They promote tumor cell invasion by the secretion of several 
growth factors, such as IL-10, VEGFA and arginase-1 (Quail et al., 2013). 
The immune cells migrate to the tumor site in response to chemoattractant 
factors. The chemokines and other chemoattractant proteins and lipids are 
produced by local cells in an injured tissue. These molecules diffuse and produce a 
concentration gradient allowing leukocyte recruitment. Many chemokines were 
shown to play a role in in tumor progression, including CXCL1, CXCL2, CXCL8, 
CCL2 and their receptors CXCR1, CXCR2, CCR2 and CCR5, among others 
(Allavena et al., 2010) (Zhao et al., 2005). The chemoattractant molecules and 
their receptors could represent important targets for the development of therapeutic 
approaches able to control tumor progression.  
A new chemoattractant protein for immune cell populations, chemerin, was 
identified in the host laboratory a decade ago. Several studies have shown the role 
of chemerin in tumor development, with a pro or anti-tumoral effect, depending on 
the type of cancer. Pachynski et al. demonstrated that chemerin expression is 
down-regulated in many human cancers such as melanoma, and that high 
chemerin expression correlates with a higher recovery rate in melanoma patients 
(Pachynski et al, 2012). However, Wang et al. showed that patients with gastric 
cancer (particularly individuals with poor prognosis or with non-intestinal type) have 
increased chemerin levels (Wang et al., 2014). 
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1.3 CHEMERIN 
The gene encoding chemerin was first described as tazarotene-induced gene 2 
(Tig2 or RARRES2). Chemerin is expressed mainly by the liver and adipose tissue, 
but also by the adrenal gland, pancreas, lung and skin (Zabel et al., 2014). The 
preprochemerin precursor form (163 amino acids) includes a typical signal peptide 
of 20 residues, which is cleaved during the import into endoplasmic reticulum. A 
prochemerin form with 143 amino acids is therefore secreted by cells, and 
represents the dominant isoform in the plasma of healthy subjects (~3 nM) 
(Mattern et al., 2014) (Due et al., 2009). Prochemerin is biologically inactive, and 
requires proteolytic processing at its C-terminus to become active. There are at 
least eight proteases involved in the cleavage of prochemerin to shorter forms, 
either active - chemerin - or inactive. These proteases include neutrophil serine 
proteases (cathepsin G and elastase), tryptase and plasmin (Figure 1.2). 
Cathepsin G and elastase are responsible to convert prochemerin into two 
isoforms of bioactive chemerin, which act as potent chemoattractant molecules for 
leucocyte populations (Mattern et al., 2014). 
Chemerin production can be regulated by metabolic or inflammatory mediators, 
including agonists of nuclear receptor (retinoids, vitamin D, glucocorticoids), factors 
associated with metabolic processes (fatty acids, insulin, glucose) and 
immunoregulatory mediators (inflammatory cytokines, LPS) (Zabel et al., 2014). 
Chemerin is able to bind to three G protein-coupled heptahelical receptors with 
high affinity: ChemR23, GPR1 and CCRL2.  
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Figure 1.2 Mechanisms of chemerin cleavage. Chemerin is first produced as 
preprochemerin, and following the co-translational cleavage of the signal peptide, it 
becomes prochemerin, the main isoform present in the plasma of healthy subjects. 
Prochemerin can be truncated in different isoforms, depending of the processing 
enzymes. The various isoforms have different functions in biological processes 
such as immune recruitment, angiogenesis or regulation of glucose metabolism 
(Adapted from Mattern et al., 2014). 
 
1.3.1. ChemR23 
ChemR23, also described as Chemokine-like receptor 1 (CMKLR1) or DEZ in 
mice, is a G protein-coupled receptor, which was described as the first receptor of 
chemerin (Wittamer et al., 2003). It was later described to bind also the lipid 
mediator resolvin E1 (RevE1) (Arita et al., 2007), although the putative interaction 
between resolvin E1 and ChemR23 is still a matter of debate. ChemR23 is 
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expressed by immune cells such as monocytes, macrophages, NK cells, and 
myeloid and plasmacytoid dendritic cells. ChemR23 expression is downregulated 
during the maturation of dendritic cells. The receptor is also expressed in non-
immune cells, including preadipocytes and adipocytes, osteoclasts, chondrocytes, 
skeletal muscle cells and endothelial cells (Bondue et al., 2012). 
GPCRs are composed of seven transmembrane helices, three intracellular loops 
and three extracellular loops. They signal through trimeric G protein G, composed 
of αβγ subunits, and a set of effectors (Wu et al., 2012)(Tuteja, 2009). GPCRs are 
activated by extracellular ligands, promoting the release of GDP from the  subunit 
of the G protein and its replacement by GTP (Wu et al., 2012) (Tuteja, 2009). The 
dissociation of Gα and G subunits allow them to bind effectors such as adenylyl 
cyclase, phospholipase C beta, PI3Ks and ion channels. These effectors regulate 
in turn various signaling cascades involving intracellular enzymes, transporters and 
channels and transcription factors (Wu et al., 2012) (Tuteja, 2009). 
Binding of chemerin to ChemR23 (KD = 4.9 nM; EC50 = 4.5 nM) promotes 
internalization of the receptor, calcium mobilization and chemotaxis of ChemR23-
expressing immune cells (Bondue et al., 2012) (Herová et al., 2015). In the host 
laboratory, Luangsay et al. showed an anti-inflammatory effect of the 
chemerin/ChemR23 system in an animal model of acute lung inflammation. They 
observed an accumulation of neutrophils in the lung and a high production of 
proinflammatory cytokines following an intranasal instillation of LPS. When 
chemerin was given together with LPS, the recruitment of neutrophils and the 
production of cytokines were milder, indicating an anti-inflammatory role of 
chemerin. In ChemR23-deficient mice, the recruitment of neutrophils to the lung 
increased compared to wild-type mice, suggesting that the anti-inflammatory effect 
of chemerin is mediated by ChemR23 (Luangsay et al., 2009). 
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1.3.2 GPR1 
GPR1 is expressed in the nervous system, placenta, ovary and testis, skin, 
adipose tissue and skeletal muscle, but not in the immune system (Zabel et al., 
2014). GPR1 binds chemerin with high affinity (KD = 5.3 nM), and internalizes 
efficiently. However, the signaling elicited by this receptor, which includes Ca2+ 
mobilization and ERK1/2 phosphorylation, is much less efficient than that promoted 
by ChemR23 (Zabel et al., 2014) (Mattern et al., 2014). The functional role of this 
receptor in the chemerin system is therefore still unclear. No evidence was 
provided so far to show cell migration mediated by GPR1. It was suggested that 
GPR1 could act as a decoy receptor, regulating the chemerin concentration in the 
plasma by its internalization and its degradation (Zabel et al., 2014).  
 
1.3.3 CCRL2 
CCRL2 (C-C Chemokine Receptor Like 2), is described as the third receptor 
having chemerin as a ligand. CCRL2 is structurally related to the family of 
chemokine receptors, sharing 40% identity with CCR1, CCR2 and CCR5 (Mattern 
et al., 2014). The human receptor is expressed by immune cells such as 
monocytes, macrophages, dendritic cells (DC), neutrophils, T cells, NK cells, mast 
cells and CD34+ precursors of the bone marrow. In mice, the receptor is expressed 
by mast cells, macrophages, dendritic cells and endothelial cells (Bondue et al., 
2011). 
CCRL2 binds chemerin with high affinity both in human and mice (KD = 1.6 nM). 
However, the binding of chemerin does not lead to internalization of CCRL2 or 
Ca2+ mobilization in cells expressing the receptor. Like other non-signaling 
chemokine receptors, CCRL2 displays structural changes in the DRYLAIV motif 
that is important for coupling receptors to G proteins (Bondue et al., 2011) (Mattern 
et al., 2014). CCRL2 is up-regulated by LPS and TNF-, suggesting a role in the 
regulation of the immune system (Bondue et al., 2012). Zabel et al. proposed that 
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CCRL2 increases the local chemerin concentration and presents it to cells 
expressing ChemR23. CCRL2-transfected cells were indeed reported to enhance 
the mobilization of Ca2+ and receptor internalization following stimulation of cells 
expressing ChemR23 by chemerin (Zabel et al., 2008). Gonzalvo-Feo et al. 
showed a role of CCRL2 in the migration of DC through the endothelium. 
Endothelial cells produce chemerin and promote the adhesion of dendritic cells, by 
up-regulating CCRL2. In this study, CCRL2 was shown to concentrate bioactive 
chemerin at the surface of endothelial cells, promoting the migration of dendritic 
cells through the endothelium (Gonzalvo-Feo et al., 2014). 
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2. AIM OF THE PROJECT 
Chemerin is a chemoattractant factor for immune cells, and is acting through 
three receptors, ChemR23, GPR1 and CCRL2. Its main function is to promote the 
migration of immune cells to inflamed tissues. Several studies have shown 
changes in circulating concentrations of chemerin in human cancers, suggesting a 
role of this chemoattractant molecule in the control of tumor progression. The aim 
of this project is to understand the role of chemerin and two of its receptors, 
CCRL2 and ChemR23, in tumor development. We will use mice deficient for each 
receptor, and the mice will receive grafts of tumor cell lines. We will observe the 
growth of tumors, as well as several processes affecting tumor growth, namely 
proliferation and apoptosis of tumor cells, the recruitment of immune cell 
populations, and the expression of angiogenic factors. 
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3. MATERIALS AND METHODS  
3.1. ANIMALS 
For all experiments, we used 6-10 week-old C57BL/6 mice, and groups included 
between 4 and 8 mice.  
C57BL/6 is a mouse strain, which is widely used in scientific research. Its most 
significant advantage is to have its entire genome sequenced. Many disease 
models have also been established in this strain and genetically modified mouse 
lines are often available on this background. As main characteristics, the C57BL/6 
mice present a low susceptibility to spontaneous tumors, making it therefore an 
excellent model for investigations in the cancer area, a high susceptibility to 
metabolic diseases, allowing the study of obesity and type 2 diabetes, a high 
incidence of hydrocephalus and microphthalmia, a low bone density and a good 
genetic stability (Mekada et al., 2009). 
The ChemR23 knock-out mice (ChemR23-/-) were obtained from DeltaGen 
(USA) and bred on the C57BL/6 background for more than ten generations, in 
order to obtain a pure genetic background. The CCRL2 knock-out mice (CCRL2-/-) 
were provided by Silvano Sozzani, (University of Brescia, Italy) (Otero et al., 2010) 
and were bred on the C57BL/6 background for ten generations. All procedures 
involving animals were approved by the Ethical Committee of the Free University of 
Bruxelles, Belgium (CEBEA).  
 
3.2. TUMOR CELL LINES 
For assessing the role of receptors in tumor growth, two tumor cell lines were 
used: B16 melanoma cells and Lewis Lung Carcinoma cells (LLC).  
The B16 cell line originates from a murine melanoma that developped in a 
C57/Bl6 mouse. It is therefore used as a syngeneic grafting model of melanoma in 
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C57/Bl6 mice. These cells can be grafted intradermally, subcutaneously or in foot 
pads. The B16 cells present a high capacity of local invasion and are highly 
metastatic, particularly although not exclusively to the lung (Bobek et al., 2010).  
The LLC line was established from a spontaneous epidermoid carcinoma that 
developed in the lung of a C57/Bl6 mouse. The cell line is usually grafted in 
syngeneic animals (C57/Bl6 mice), in which it is highly tumorigenic and display a 
high capacity to metastasize, predominantly to the lung (Kellar et al., 2015). 
Both cell lines were grafted into syngeneic C57BL/6 mice. The cell lines were 
grown in RMPI 1640 medium (Gibco, USA) containing 1% glutamine, 10% 
decomplemented fetal bovine serum (FBS, Gibco), 100 U/ml penicillin, 100 g/ml 
streptomycin (Gibco), 1% non-essential amino-acids (Gibco) and 1% sodium 
pyruvate (Gibco), in an incubator at 37ºC and 5% CO2. 
 
3.3. GRAFTING OF TUMOR CELL LINES  
Tumor cells were detached from the plates with a solution of 2% trypsin (Gibco) 
and 100 mM EDTA (Sigma, USA) in HBSS CaCl2-MgCl2 culture medium (Gibco, 
USA). Live cells were counted by the Trypan Blue dye exclusion test. 1.106 cells 
were injected subcutaneously in the back or flank of ChemR23+/+, ChemR23-/-, 
CCRL2+/+ or CCRL2-/- mice. To follow tumor development, the size of tumors was  
measured daily following two perpendicular axes with a caliper, starting three days 
after injection, The tumor volume was estimated by the formula: .volume = 0.52 x 
(width)2 x length. 
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3.4. TUMOR DIGESTION  
Mice are sacrificed at different days, and the tumors were collected, cut into 
small pieces with scissors, and incubated in a digestion solution (10 mg/mL 
collagenase D (Roche, Switzerland), 2000 U/mL DNase I (Roche, Switzerland), 5% 
FBS in HBSS) for 1h30 at 37ºC, with gently agitation. The cell suspension was 
filtered through a 70 µm filter to remove residual debris, and centrifuged at 450 g 
for 5 minutes. The number of cells present in this suspension was counted in a 
Neubauer chamber, following staining of dead cells by the Trypan blue dye.  
 
3.5. FLOW CYTOMETRY ANALYSIS 
Flow cytometry is a powerful method that analyzes individual cell characteristics, 
by passing a large number of individual cells in rapid succession in front of a 
detector. Cells are labeled with specific antibodies coupled to fluorochromes with 
the aim of characterizing mostly cell surface markers, but also intracellular 
markers, present in the cell populations of interest (Jahan-Tigh et al., 2012). 
This technique can be performed with blood leucocytes, cells differentiated in 
culture, or cell populations prepared from a variety of tissues, following digestion of 
the tissue and sieving through a mesh in order to obtain a cellular suspension. The 
cell suspension is incubated with antibodies coupled with fluorochromes such as 
fluorescein isothiocyanate (FITC), phycoerythrin (PE) or allophycocyanin (APC) 
(Jahan-Tigh et al., 2012). 
The labeled cell suspension is thereafter introduced into the flow cytometer. The 
cells are passed through a narrow column that lines them one after the other. The 
fluorochromes are detected, following illumination by one or several laser beams, 
according to the wavelength of the emitted light, which is is analyzed by an optical 
system made of dichroic mirrors and detectors. Information on various surface 
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markers can therefore be collected simultaneously for the analysis of complex 
populations (Jahan-Tigh et al., 2012). 
Besides the fluorescence data, the cytometer also records optical parameters: 
the forward scatter (FSC), which is a measure of the size of the cells, and the side 
scatter (SSC), indicating the granularity of the cells. This analysis is based on the 
angle of light emitted from the analyzed cells (Jahan-Tigh et al., 2012). 
 
Figure 3.1 Flow cytometry. The cell suspension is stained with fluorescent 
antibodies, and passed through the detection system. The light emitted by 
fluorochromes is passed through dichroic mirrors and various filters detected by a 
photomultiplier and transferred for analysis to a computer. The result of this 
analysis is displayed as histograms or two-dimensional dot-plots. [Adapted from 
Brown et al. (2000) and Jahan-Tigh et al. (2012)] 
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In this work, to determine the different subsets of leukocytes present in tumors, 
the cells isolated from tumors were stained with fluorescent dye-labeled antibodies 
and analyzed by flow cytometry. 2.105 cells were resuspended in 100 µL of FACS 
solution (1% FBS, 5 mM EDTA in PBS) and centrifuged at 450 g for 5 minutes at 
4ºC. To block unspecific binding, the cells were incubated with anti-CD16/CD32 
antibodies for 20 minutes at 4ºC, are washed by centrifugation at 450 g for 5 
minutes at 4ºC. For staining of cell membrane markers, the following antibodies 
were used: FITC- (Fluorescein Isothiocyanate), R-PE- (R-Phycoerythrin), APC- 
(Allophycocyanin) or APC/Cy7- (Allophycocyanin/cyanine 7) conjugated anti-CD45; 
APC-conjugated anti-CD3; R-PE/Cy7- (R-phycoerythrin/cyanine 7) conjugated anti-
TCR; A488- or V450-conjugated anti-CD4; PerCP/Cy5.5- (Peridinin Clhorophyll 
Protein Complex/Cyanine 5.5) or V500-conjugated anti-CD8; FITC- or  
PerCP/Cy5.5-conjugated anti-CD11b; PerCP/Cy5.5- or R-PE/Cy7-conjugated anti-
Gr1; PE-conjugated anti-Ly6G; EF450-conjugated anti-Siglec H; R-PE/Cy7-
conjugated anti-B220; V450- or APC-conjugated anti-CD11c; FITC- or EF450-
conjugated anti-F4/80; PE-conjugated anti-CD49b antibodies (eBioscience, USA). 
Viability dye 7-AAD (eBioscience, USA) and Hoescht 33342 (Life Technologies, 
USA) were used to stain live cells. 
For staining of intracellular markers, the cells were fixed with 2% 
paraformaldehyde (PFA) for 15 minutes, and permeabilized in 0.5% saponine in 
FACS solution. Cells were further incubated with FITC-conjugated Ki67 antibody 
(eBioscience, USA) for 45 minutes. After a washing step, the cells were analyzed 
on a FacsAria II flow cytometer (Becton Dickinson, USA). 
To identify apoptotic cells, 2.105 cells were incubated with eF450-conjugated anti-
annexin V antibody for 15 minutes at room temperature (RT) in the dark. Cells 
were washed twice and resuspended in FACs buffer. The viability dye 7-AAD was 
added and cells were analyzed on a FacsAria II flow cytometer.  
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3.6. IMMUNOFLUORESCENCE MICROSCOPY 
Immunofluorescence microscopy is a highly used technique in scientific 
research, through the use of fluorescent antibodies that allow detecting specific 
target antigens. There are two types of immunofluorescence labeling, direct and 
indirect. Direct immunofluorescence (DIF) refers to the use onto the tissue of 
fluorescently tagged antibodies directed against the target antigen. Indirect 
immunofluorescence requires two successive steps. First, a primary antibody, 
which is not tagged, binds to the target antigen. Then, a secondary antibody 
labeled fluorescently, binds to the primary antibody, and thus, and generates a 
specific staining. This technique is a bit more complex than the first, because it 
involves more incubation steps, but it is more sensitive, because of the 
amplification step brought by the secondary antibody. It is therefore less affected 
by the nonspecific auto-fluorescence that is observed in some tissues (Odell et al., 
2013). 
In this project, we have used confocal microscopy instead of conventional 
microscopy, because confocal microscopy has several advantages that 
conventional fluorescence microscopy has not. The conventional microscope has 
as major disadvantage that only thin sections can be visualized, requiring the use 
of fixative agents and embedding media or freezing the samples prior to 
sectionning. Confocal microscopy creates virtual sections through much thicker 
samples, providing high quality images and an increased level of details than 
conventional microscopy, starting from unfixed and possibly live tissues. In 
confocal microscopy, an intense input light beam illuminates the samples in a 
scanning mode, but only the emitted light originating from a specific plane in the 
sample is focused through the lens of the microscope ans visualized. The light 
emitted outside the focal plane is blocked by passage through a narrow pinhole, in 
order to make easier the visualization of the focal plane. Focused planes are 
scanned and reconstructed by a computer system, and several planes can be 
combined to reconstruct three-dimensional images (Nwaneshiudu et al., 2012). 
Role of chemerin and its receptors in mouse models of tumorigenesis 
 
 
 
 
Bárbara Sofia Marques da Silva 
20 
 
In this work, tumors were embebbed in OCT (Sakura, Japan) and stored at -
80ºC. Tumor cryosections of 8-12 µm were made and placed on Superfrost Plus 
slides (Thermo Scientific, USA).  Sections were fixed in acetone for 10 minutes and 
air dried for 2-3 hours. To block unspecific binding, sections were incubated in a 
solution of 3% BSA and 0.1% Triton X100 in PBS. We used APC-conjugated anti-
CD45, FITC-conjugated anti-Ki67, PE-conjugated anti-CD31, purified anti-cleaved 
caspase 3 (eBioscience) and A488-conjugated rabbit anti-IgG (Life Technologies, 
USA) antibodies. The slides were mounted with coverslips and mounting medium 
(2% Glycergel Dabco , Sigma, USA). Tumor sections were analyzed on a Zeiss 
LSM 780 confocal microscope (Zeiss, Germany), and the images collected and 
analyzed by Carl Zeiss Microscopy and Image J softwares. 
 
3.7. HEMATOXYLIN/EOSIN STAINING 
Hematoxylin and eosin coloration constitutes the most classical staining 
procedure for histological examination of tissue samples. It allows the recognition 
of different cell types and their organization in tissues, as well morphological 
changes, thus allowing the diagnosis of various diseases such as cancer. This 
technique is therefore useful for complementing the analysis of tissues by 
immunofluorescence in order to visualize the overall structure of the analyzed 
samples, which is not always obvious from immunofluorescence data (Fisher et al., 
2006). 
This procedure allows to stain intracellular complements such as the nucleus 
and the cytoplasm and delimits the cells by highlighting the cellular membranes. 
Hematoxylin stains nucleic acids, because of its affinity for basophilic substances, 
resulting in a blue/purple staining. Eosin has affinity to acidophilic substances and 
labels non-specifically proteins by a pink staining. Thus, in a normal tissues, the 
nuclei are stained blue, while the cellular membrane and cytoplasm display 
different shades of pink (Fisher et al., 2006). 
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In this work, the tumor sections were passed successively into 90% isopropanol, 
an hematoxylin solution, 0.5% lithium carbonate, 1% eosin Y solution, 70%, 90% 
and 100% ethanol, toluene (VWR Chemicals, USA) before mounting with 
coverslips and Entellan solution (Merck, USA). Sections were analyzed on a 
AxioImager Z1 microscope (Zeiss, Germany) and the images obtained were 
treated by AxioVision and Image J softwares.  
 
3.8. ELISA 
Enzyme-linked immunosorbent assays (ELISA) are important tools for 
biomedical research, but also for medical diagnosis. These assays have the ability 
to detect all types of biological molecules at minimal concentrations (Gan et al., 
2013).  
An antigen binding antibody is coated on a solid surface allowing the binding 
of target molecules. The antigen, which is added in the liquid phase, is detected by 
a specific antibody, which in turn is detected by a secondary antibody. The 
secondary antibody is linked to the generation of a chromogenic substrate, which 
allows a color or fluorescence change, indicating the presence of antigen. The 
level of fluorescence is measured by a spectrophotometer, quantitatively or 
qualitatively. There are four types of ELISA: indirect, competitive, sandwich and 
multiple, but we focus in the sandwich technique (Gan et al., 2013). 
Sandwich ELISA is used to recognize a specific antigen in a sample. A 
microtiter plate is coated with a capture antibody specific to the target antigen. 
Non-specific binding is blocked with bovine serum. The sample is added, followed 
by the primary antibody specific for the target antigen. The secondary antibody, 
coupled to an enzyme, then binds to the primary antibody. Subsequently, the 
substrate is added to allow reaction with the enzyme, and cause a change in color 
or fluorescence. This technique has the advantage of using two antibodies specific 
for the antigen of interest, thereby increasing its specificity (Gan et al., 2013). 
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In our experiments, the concentration of total chemerin in mouse plasma 
was assessed by a Sandwich ELISA (R&D Systems, USA). Blood from CCRL2 +/+ 
and -/- mice was collected in presence of  0.5M EDTA and centrifuged for 10 
minutes at 300 g, and the plasma was recovered. Wells from 96 well plates were 
coated overnight at RT with 4 µg/mL purified anti-chemerin antibody diluted in 
PBS. The plates were washed with a wash buffer (0.05% Tween 20 in PBS) and 
unspecific binding sites blocked with 1% BSA in PBS for 1 hour at RT. After 
washing, recombinant chemerin (used as standard) and experimental samples 
were diluted in PBS containing 1% BSA and incubated in the wells for 2 hours at 
RT. Biotinylated anti-chemerin antibody (1 µg/mL) was added and incubated for 2 
hours at RT. The plate was washed and streptavidin-HRP (Horseradish 
peroxidase, R&D Systems, USA) was added for 20 minutes at RT in the dark. After 
washing, the substrate solution (H2O2 + 3,3′,5,5′-tetramethylbenzidine, TMB) was 
added for 20 minutes at RT in the dark. The reaction was stopped by addition of 2 
N H2SO4. The optical density was measured on a Biorad spectrophotometer at 450 
nm (reference 570 nm).  
 
3.9. RT-QPCR 
Retro-transcriptase quantitative PCR allows the analysis of gene expression by 
the assaying the amount of a specific RNA species in cells or tissues. The RNA is 
first retro-transcribed into complementary DNA (cDNA), which, in turn, is amplified 
by PCR, and the amount of the PCR product is quantified along the cycles. 
In this work, the main objective is the amplification of a number of specific genes 
used as markers of inflammation or angiogenesis. Thus, we used specific primers 
(forward and reverse) for each of these genes. To visualize the amplification in 
real-time, either fluorescent dsDNA binding dyes (such as SYBR Green) or 
fluorescent probes (TaqMan) are used. Thus, the amplified genetic sequences emit 
fluorescence, which is recorded during the amplification process, and these data 
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are transferred to a computer analysis system. This powerful technique allows then 
the quantitative analysis of mRNA for a given gene (Gentle et al, 2001). 
This quantification may be absolute or relative. The absolute quantification 
allows knowing the number of copies of a specific transcript through the use of a 
reference curve, which is normally done with different amounts of a plasmid 
containing the sequence of interest. The relative quantification of expression 
correlates the amount of target sequence with the expression of one or several 
reference genes that are not expected to vary too much from tissue to tissue or in 
different experimental conditions. These reference genes are usually chosen 
amongst housekeeping gene, provided the relative stability of their expression. 
This second method is used to compare changes in the expression of a gene in 
different samples (Santos et al., 2004). 
To extract RNA from the tumors, the tumors were sonicated in 1 mL of Trizol 
solution (Invitrogen, UK) in RNase-free tubes, and stored at -80ºC. After thawing, 
200 µL of chloroform was added to the samples, and the tubes were centrifuged at 
12000 rpm for 15 minutes at 4ºC. The upper phase was transferred to a new tube, 
and 500 µL of isopropanol was added to precipitate RNA. The samples were 
incubated 10 minutes at RT, and centrifuged at 12.000 rpm for 10 minutes at 4ºC. 
The supernatant was removed and 1 mL of 75% ethanol was added. The samples 
were centrifuged at 7500 rpm during 5 minutes at 4ºC. The supernatant was 
completely removed, and the pellets were air dried for 30 minutes. The pellet was 
next resuspended in 20 µL of RNAse free water. The concentration of RNA is 
measured in a Nanodrop (USA). Complementary DNA (cDNA) was obtained from 
2 µg of mRNA by reverse transcription using SuperScript III (Invitrogen, UK) 
according manufacturer’s instructions.  
The expression of angiogenic and inflammatory factors was determined by 
relative quantitative PCR (qPCR) using SYBR Green Power kit (Invitrogen, UK) 
and using the primers listed in Table 3.1. The qPCR thermocycling conditions for 
all genes were 10 min at 95˚C, followed by 40 cycles of denaturation at 95˚C, 
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annealing at 60˚C and extension at 72˚C, all for 15 sec. The quantitative PCR was 
performed using a 7500 Real-Fast thermocycler (Applied Biosystems, USA). The 
expression levels were normalized using GAPDH as a reference housekeeping 
gene.  
 
Table 3.1. Primers of angiogenic and inflammatory factors used in 
quantitative RT-PCR experiments. 
Gene Terminal Sequence 
Glyceraldehyde-
3-Phosphate 
Dehydrogenase 
mGAPDH fw AAG-GGC-TCA-TGA-CCA-CAG-TC 
mGAPDH rev CAG-GGA-TGA-TGT-TCT-GGG-CA 
Thrombospondin 
1 
mTSP1 fw ACT-TCA-CCT-TTG-CCA-CCT-C 
mTPS1 rev AGA-CTC-TGG-AAT-GCG-GTT-G 
Vascular 
Endothelial 
Growth Factor A 
mVEGFA fw GGC-AGC-TTG-AGT-TAA-ACG-
AAC 
mVEGFA rev TGG-TGA-CAT-GGT-TAA-TCG-GTC 
Fibroblast 
Growth Factor 2 
mFGF2 fw TCT-ACT-GCA-AGA-ACG-GCG 
mFGF2 rev CTC-CCT-TGA-TAG-ACA-CAA-
CTC-C 
Transforming 
Growth Factor, 
Beta 1 
mTGFb fw GGA-GAG-CCC-TGG-ATA-CCA-AC 
mTGFb rev CAA-CCC-AGG-TCC-TTC-CTA-AA 
Interleukin 10 mIL10 fw ATT-TGA-ATT-CCC-TGG-GTG-
AGA-AG 
mIL10 rev CAC-AGG-GGA-GAA-ATC-GAT-
GAC-A 
Interleukin 6 mIL6 fw TCC-AGT-TGC-CTT-CTT-GGG-AC 
mIL6 rev GTA-CTC-CAG-AAG-ACC-AGA-GG 
Interleukin 1b mIL1b fw CAC-AGC-AGC-ACA-TCA-ACA-AG 
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mIL1b rev GTG-CTC-ATG-TCC-TCA-TCC-TG 
Tumor necrosis 
factor alpha 
mTNFa fw ATG-AGA-AGT-TCC-CAA-ATG-GC 
mTNFa rev CTC-CAC-TTG-GTG-GTT-TGC-TA 
Matrix 
Metalloprotease 
9 
mMMP9 fw TAA-GGA-CGG-CAA-ATT-TGG-TT 
mMMP9 rev CTT-TAG-TGG-TGC-AGG-CAG-AG 
Matrix 
Metalloprotease 
10 
mMMP10 fw CCT-GTG-TTG-TCT-GTC-TCT-
CCA-AGA 
mMMP10 rev CGT-GCT-GAC-TGA-ATC-AAA-
GGA-C 
Chemokine (C-X-
C Motif) Ligand 1 
mCXCL1 fw TGC-ACC-CAA-ACC-GAA-GTCA-T 
mCXCL1 rev TTG-TCA-GAA-GCC-AGC-GTT-
CAC 
Chemokine (C-X-
C Motif) Ligand 2 
mCXCL2 fw CGC-TGT-CAA-TGC-CTG-AAG 
mCXCL2 rev GGC-GTC-ACA-CTC-AAG-CTC-T 
Chemokine (C-C 
Motif) Ligand 2 
mCCL2 fw AAC-TCT-CAC-TGA-AGC-CAG-
CTC-T 
mCCL2 rev CGT-TAA-CTG-CAT-CTG-GCT-GA 
Hypoxia 
Inducible Factor 
1, Alpha Subunit 
mHIF1a fw GGT-TCC-AGC-AGA-CCC-AGT-TA 
mHIF1a rev AGG-CTC-CTT-GGA-TGA-GCT-TT 
 
3.10. HIGH PRESSURE LIQUID CHROMATOGRAPHY (HPLC) 
Chromatography is an analytical technique that allows separation of 
different molecules on the basis of their structure and/or physicochemical 
properties. The sample passes through a stationary phase where the molecules 
will have different interactions with the support, leading to the separation of 
molecules (Kupiec, 2004). 
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The HPLC instrumentation consists of pumps, injectors for the samples, 
columns, detectors and a display system. The main component is the column 
where the chromatographic separation occurs. The pump, allowing to apply high 
pressure onto the column, is necessary to transport efficiently the mobile liquid 
phase containing the components through the fixed phase of the column. The 
samples are introduced into the liquid phase through an injector loop. The 
detection method used to analyze the components separated by the column is very 
important and needs to be adapted to the nature of the molecules of interest. 
Fractions of the liquid phase flowing out of the column are collected for further 
analysis or subsequent purification steps (Kupiec, 2004). 
In our experiments, the aim was to purify chemerin from mouse plasma 
samples. For this purpose, we used an HPLC setting with a heparin column. 
Heparin is a negatively charged polysaccharide, thereby allowing binding of 
positively charged biomolecules such as enzymes, growth factors, hormones or 
chemokines. Chemerin is known to bind heparin efficiently and this column is 
therefore well adapted for a first purification step. Heparin columns constitute an 
absorption chromatography, which is useful to concentrate molecules at low 
concentrations in the starting sample, as is the case of active chemerin in the blood 
(Xiong et al., 2008). 
In order to detect the bioactive chemerin in the HPLC fractions, we used a 
calcium-mobilization assay based on the bioluminescence of aequorin. The 
aequorin-based assay enables the analysis of the interaction of proteins with 
GPCRs coupled to the release of intracellular Ca2+. In this assay, we used cells 
expressing apoaequorine, the G16 protein subunit, allowing to redirect the 
coupling of most GPCRs toward phospholipase C, and the target receptor (in this 
case, ChemR23). The cells are incubated with coelenterazine (the apoaequorine 
cofactor) in order to reconstitute the active enzyme aequorin. The aequorin is 
activated by the increase in cytosolic Ca2+, following activation of the receptor by 
its ligand. This creates a rapid and transient luminescence signal, which is 
Role of chemerin and its receptors in mouse models of tumorigenesis 
 
 
 
 
Bárbara Sofia Marques da Silva 
27 
 
proportional to the calcium concentration and is recorded by a luminometer. Thus, 
activation of the recombinant GPCR expressed in the reporter cell line results in 
the generation of aequorin bioluminescence, which is recorded by a luminescence 
reader (Oksa et al., 2009). 
The concentration of bioactive chemerin in the blood of CCRL2+/+ and -/- mice 
was following fractionation of the samples by HPLC. The plasma samples were 
diluted ten times in a 20 mM phosphate buffer (pH 8.0) and filtered through 4 µm, 
0.45 µm and 0.22 µm filters. The samples were placed on a HiTrap Heparin HP 
column (GE Healthcare) with a capacity of 1 mL. The elution was performed with a 
gradient of NaCl (20 to 700 mM), and 1 mL of fractions were collected. CHO 
(Chinese hamster ovary) cells, expressing ChemR23, apoequorin and Gα16, were 
collected from culture dishes, resuspended in an aequorin buffer (DMEM 
containing 0.5% BSA and 5 M coelenterazine H) and incubated for 4 hours under 
gentle agitation in the dark. The cells (50,000 cells in 50 L) were added to wells 
containing different concentrations of the collected fractions or recombinant mouse 
chemerin used as standard. The luminescence was measured for 30 s in a LB 960 
luminometer (Berthold Technology). The results were normalized to the response 
obtained with 20 M ATP acting through endogenous receptors of CHO cells.  
 
3.11. STATISTICAL ANALYSES 
Statistical significance was calculated by using the Mann-Whitney U test or 
Wilcoxon test, with the GraphPad Prism 6 software.  
The Mann-Whitney test is a non-parametric test used to compare the distribution 
of a variable using two independent samples. It is used as an alternative to the 
Student t test for independent testing, when the number of samples is low or too 
different across groups, or when the variances are heterogeneous (Rank et al., 
1988). 
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The Wilcoxon test is a non-parametric test used when two independent groups 
are submitted to the same conditions. This test is appropriate when analyzing the 
data of repeated measurements made in two conditions (Grok, n.d.).  
For both tests, the differences were considered significant at P value < 0,05 ( * 
represent p value < 0,05).  
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4. RESULTS 
The aim of this project is to understand the influence of chemerin receptors, 
ChemR23 and CCRL2, in a mouse model of tumorigenesis. We use mice deficient 
for each of these receptors and grafted them with tumor cell lines to observe the 
influence of the receptors on tumor implantation, immune cell recruitment and 
angiogenesis. Two tumoral cell lines derived from C57Bl6 mice were used, the B16 
melanoma and Lewis lung carcinoma (LLC) cell lines. 
 
4.1 CHEMR23 IS NOT INVOLVED IN THE CONTROL OF B16 TUMOR 
DEVELOPMENT 
ChemR23 is the main receptor of chemerin. It is described to induce the 
migration of immune cell populations known to influence tumor progression, such 
as NK cells, macrophages and dendritic cells (Vermi et al., 2005). To analyze the 
effect of ChemR23 deficiency on tumor development, 1.106 B16 tumor cells were 
injected in the flank of ChemR23+/+ and ChemR23-/- mice, and we measured the 
tumor growth during ten days after tumor implantation (Figure 4.1).  
We observed that tumors from ChemR23+/+ and ChemR23-/- mice became 
detectable and developed with the same time frame. These data suggest that 
ChemR23 does not play a major role in the control of tumor development, at least 
in this particular model. ChemR23 allowing the migration of dendritic cells, NK cells 
and macrophages, we determined whether the absence of ChemR23 affects the 
immune cell recruitment to the tumor site. 
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Figure 4.1 ChemR23+/+ (n=5) and ChemR23-/- (n=5) mice develop tumor in a 
similar way. 1.106 B16 cells were injected subcutaneous into ChemR23+/+ (circle) 
and -/- (square) mice. The size of tumors was measured daily for 10 days after cell 
implantation. The tumor size is calculated according to the formula: Volume = 0.52 
x (width)2 x length. This experiment is representative of 3 independent 
experiments.  
 
Ten days after tumor implantation, tumors were removed and digested, and 
immune cell populations infiltrating the tumors were identified by flow cytometry. 
We first analyzed the recruitment of CD45-positive cells as a measure of total 
immune cells (Figure 4.2 A). No difference was observed between ChemR23+/+ 
and ChemR23-/- mice. We next analyzed the different subsets of immune cells 
among the CD45+ population. The proportion of macrophages (CD11b+ F4/80+ 
CD11c- cells), myeloid dendritic cells (CD11c+ Siglec H- cells), plasmacytoid 
dendritic cells (CD11c+ Siglec H+ cells), MDSC (CD11b+ Gr1+ cells), T cells (CD3+ 
cells) and NK cells (NK1.1+ CD3- cells) were not significantly different between the 
two groups (Figure 4.2 B-E). These results show that ChemR23 does not affect 
significantly the recruitment of immune cells in this model. They are consistent with 
the absence of effects on tumor growth, and suggest that ChemR23 does not play 
a major role in tumor development neither in the immune cell recruitment to the 
tumor site in this B16 melanoma model.  
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Figure 4.2. The immune cell recruitment to B16 tumors is not affected by 
ChemR23. 1.106 B16 cells were injected subcutaneously in the back of 
ChemR23+/+ and -/- mice. The mice were sacrificed 10 days later, and the tumors 
were removed and digested.  The immune cell populations were analyzed by flow 
cytometry. (A) Percentage of total immune cells (CD45+). (B-E) Proportion of 
immune cells subsets among the CD45+ population: macrophages (CD11b+ F4/80+ 
CD11c-), myeloid dendritic cells (CD11c+ Siglec H-), plasmacytoid dendritic cells 
(CD11c+ Siglec H+), MDSC (CD11b+ Gr1+), T cells (CD3+) and NK cells (NK1.1+ 
CD3-). This experiment is representative of 3 independent experiments. None of 
the differences between the two groups was statistically significant. 
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4.2 THE ABSENCE OF CCRL2 LEADS TO A DECREASE IN TUMOR GROWTH. 
Previous results suggested that the protective effects of chemerin on tumor 
development demonstrated both in the host laboratory and in the literature 
(Pachynski et al, 2012) are not entirely mediated by ChemR23. Chemerin is also 
able to bind CCRL2 , which is also expressed on immune cells. In order to 
determine whether CCRL2 is involved in the control of tumor development, 1.106 
B16 cells were injected in CCRL2+/+ and CCRL2-/- mice, and we measured the 
tumor growth during ten days after tumor implantation (Figure 4.3 A). CCRL2+/+ 
and CCRL2-/- mice developed tumors at about the same time, but the tumors 
remained smaller in CCRL2-/- mice than in CCRL2+/+ mice. These data suggest that 
CCRL2 has a pro-tumoral effect in this particular model. To confirm the effects of 
CCRL2 on tumor development, we used another tumor cell line, the Lewis lung 
carcinoma cell line (LLC). 1.106 cells were injected subcutaneously in CCRL2+/+ 
and -/- mice and the tumor size was measured daily (Figure 4.3 B). We observed 
the same effect of CCRL2-deficiency as for B16 tumors, with a slower growth rate 
in CCRL2-/- mice.  
 
Role of chemerin and its receptors in mouse models of tumorigenesis 
 
 
 
 
Bárbara Sofia Marques da Silva 
33 
 
 
Figure 4.3. B16 and LLC tumors develop more slowly in CCRL2-deficient 
mice (A) CCRL2+/+ and CCRL2-/- mice were injected with B16 cells and sacrificed 
ten days after implantation (n=8 per group) (B) CCRL2+/+ and CCRL2-/- mice were 
injected with LLC cells and sacrificed 13 days after implantation (n=5 per group). 
The statistical test used is a Mann-Whitney test. *,** and *** represent respectively 
p values of < 0.05, < 0.01 and < 0.001. 
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4.3 THE PLASMA CHEMERIN CONCENTRATION IS NOT ALTERED IN CCRL2-
DEFICIENT MICE 
CCRL2 is expressed in immune cells, however this receptor is described as 
non-functional (Bondue et al., 2012). A potential role of CCRL2 could be the 
presentation of chemerin to Chem23-expressing cells (Yoshimura et al., 2010). 
Binding of chemerin to CCRL2 could therefore affect the distribution of chemerin 
and affect the concentration of the protein in the circulation. To better understand 
how CCRL2 affects tumor development, we therefore determined the 
consequences of CCRL2 deficiency on the plasma concentration of chemerin. 
Blood samples were collected from CCRL2+/+ and CCRL2-/- mice and total 
chemerin levels were measured by ELISA. We observed the same concentration of 
plasmatic total chemerin in CCRL2+/+ and CCRL2-/- mice. These results suggest 
that plasmatic chemerin is not affected by the presence or absence of CCRL2 
(Figure 4.4 A). 
Prochemerin is the major form of circulating chemerin in the blood. Chemerin 
becomes active after cleavage by proteases, in particular in an inflammatory 
context. We assessed the concentration of bioactive chemerin from plasma in 
CCRL2+/+ and CCRL2-/- mice. Chemerin was purified by chromatography on a 
heparin column, and its activity was evaluated by a calcium-mobilization assay 
based on the luminescence of aequorin. In Figure 4.4B, we observed that the 
concentration of bioactive isoforms of chemerin in CCRL2 /+ and CCRL2-/- mice is 
similar. These results show that plasmatic levels of bioactive chemerin are not 
affected by the absence of this receptor. With these results, we can conclude that 
the concentrations of bioactive chemerin or its inactive precursor are not changed 
between CCRL2+/+ and CCRL2-/- mice in basal conditions.  
We next determined whether the tumor development affects the levels of 
chemerin. Three days after tumor cell implantation, blood samples were collected 
from CCRL2+/+ and CCRL2-/- mice, and chemerin levels were quantified by ELISA. 
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We found that chemerin levels were moderately increased in tumor-bearing 
animals (Figure 4.4 C), when compared to basal conditions (Figure 4.4 A). The 
increase was however similar in the two groups, suggesting that chemerin levels 
are not affected by CCRL2 in a tumoral context.   
 
Figure 4.4. The circulating levels of chemerin are not altered in CCRL2 
knock-out mice. Blood samples were collected from CCRL2+/+ and CCRL2-/- mice, 
and plasma was recovered. The levels of total and bioactive chemerin were 
measured by ELISA and a functional assay based on aequorin luminescence, 
respectively. (A) Total chemerin concentration in CCRL2+/+ and CCRL2-/- mice, in 
basal conditions, by ELISA. (B) Active chemerin concentrations in CCRL2+/+ and 
CCRL2-/- mice, in basal conditions, by the aequorine-based assay. (C) Total 
chemerin concentration in CCRL2+/+ and CCRL2-/- mice, three days after B16 tumor 
implantation. 
 
4.4 CCRL2 DOES NOT AFFECT THE IMMUNE CELL RECRUITMENT TO B16 
AND LLC TUMORS 
CCRL2 is expressed on immune cells such as plasmacytoid dendritic cells, mast 
cells and macrophages. To understand the effect of CCRL2 in anti-tumor immunity, 
we analyzed the recruitment of immune cells to B16 tumors. The tumors developed 
by CCRL2+/+ and CCRL2-/- mice are removed and digested ten days after 
implantation, and the main immune cell subsets were analyzed by flow cytometry.  
We first analyzed the recruitment of total immune cells (CD45-positive cells), 
and no difference was observed between the two groups of mice (Figure 4.5). We 
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next analyzed the different subsets of immune cells among CD45+ cells. The 
proportion of macrophages, myeloid dendritic cells, plasmacytoid dendritic cells, 
MDSC, T cells and NK cells were similar in CCRL2+/+ and CCRL2-/- mice (Figure 
4.5), suggesting that CCRL2 does not affect significantly the recruitment of immune 
cells in this model.  
 
Figure 4.5 The immune cell recruitment to B16 tumors is not affected by 
CCRL2, at day 10 of tumor growth. 1.106 B16 cells were injected subcutaneously 
in the back of CCRL2+/+ and CCRL2-/- mice. The mice are sacrificed 10 days after, 
the tumors were collected and digested. The first graph shows the percentage of 
total immune cells (CD45+), and the next graphs are representative of immune 
cells subsets: macrophages (CD11b+ F4/80+ CD11c-), dendritic cells (CD11c+ 
CD11b+), plasmacytoid dendritic cells (CD11c+ Siglec H+), MDSC (CD11b+ Gr1+), T 
cells (CD3+) and NK cells (NK1.1+ CD3-). This data set is representative of 3 
independent experiments. 
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We postulated that CCRL2 could affect the immune cell recruitment only at early 
stages of tumor development. We therefore performed the same experiment, but 
collected the tumors at day 3 and day 6 of tumor development. We observed that 
the total number of immune cells (Figure. 4.6 A) present in the tumor is similar 
between CCRL2+/+ and CCRL2-/- mice, at day 3 and day 6 of tumor development. 
We also characterized several subsets of immune cells. The proportion of NK cells, 
dendritic cells (CD11c+ CD11b+), and total CD11b+ cells (including macrophages 
and MDSC) were similar in CCRL2+/+ and CCRL2-/- mice, in the two time points 
(Figure 4.6 B-E). 
These results suggest that CCRL2 does not affect the proportion of immune cell 
recruitment at different stages of tumor development. We confirmed our results by 
performing immunofluorescence staining of immune cells on tissue sections, to 
determine the distribution of the populations in the tumor and its microenvironment. 
The tumors were recovered from wild-type and CCRL2 knock-out mice at day 3 
and day 6 of tumor development. Sections of tumors were staining with an anti-
CD45 antibody to identify immune cell. The proliferating tumor cells were identified 
with an anti-Ki67 antibody. 
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Figure 4.6. The immune cell recruitment to tumors is not affected by CCRL2, 
at day 3 (top panels) and day 6 (bottom panels) of tumor growth. 1.106 B16 
cells were injected subcutaneously in the back of CCRL2+/+ and CCRL2-/- mice. 
The mice were sacrificed 3 and 6 days later, and the tumors were recovered and 
digested. The immune cell populations were analyzed by flow cytometry. (A) Total 
immune cells (CD45+). (B-E) Immune cells subsets amongst CD45+ cells: NK cells 
(NK1.1+ CD3-), dendritic cells (CD11c+ CD11b+ and CD11c+ CD11b-) and CD11b+ 
cells (macrophages and MDSC). This data set is representative of 6 independent 
experiments. 
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Figure 4.7. CCRL2+/+ and CCRL2-/- mice present similar proportion and 
location of immune cells in tumors. 1.106 B16 cells were injected 
subcutaneously in the back of CCRL2+/+ and CCRL2-/- mice. The mice were 
sacrificed 3 and 6 days later, the tumors were recovered and embedded, without 
fixation, in OCT.  Immunofluorescente staining was performed on tumor sections 
from CCRL2+/+ and CCRL2-/- mice. Proliferating cells were stained with an anti-
Ki67 antibody (green) and immune cells with an anti-CD45 antibody (pink). The 
nuclei were stained with Hoescht 33342 (blue). Magnification is x10 for panels A, B 
and C,and x20 for panel D. This data set is representative of 3 independent 
experiments.  
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To confirm that CCRL2 does not affect the immune cell recruitment to tumors, 
we performed the same experiments on LLC tumors, 10 days after tumor 
implantation. We injected 1.106 LLC cells in CCRL2+/+ and CCRL2-/- mice, and 
sacrificed them ten days after the graft. We removed and digested the tumors and 
analyzed the immune populations by flow cytometry. We observed that the 
proportion of CD45+ cells is similar in CCRL2+/+ and CCRL2-/- mice (Figure 4.8). 
The immune cell subsets (T cells, NK cells, dendritic cells and MDSC) were also 
similar in both groups.  
 
Figure 4.8. The immune cell recruitment is not affected by CCRL2 in LLC 
tumors. Flow cytometry of immune cells present in LLC tumors from CCRL2+/+ and 
CCRL2  -/- mice. The first graph shows the percentage of total immune cells 
(CD45+), and the next graphs are representative of immune cells subsets: T cells 
(CD3+), NK cells (NK1.1+), dendritic cells (CD11c+ CD11b+) and MDSC (CD11b+ 
Gr1+). This experiment is representative of 3 independent experiments. 
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We conclude that the decrease in tumor size observed in CCRL2-/- mice is 
not dependent on changes in the concentration of chemerin in the blood, neither to 
the number or proportion of immune cells recruited to the tumor site.  
 
4.5 CCRL2 DOES NOT INFLUENCE THE PROLIFERATION OF TUMOR CELLS, 
BUT AFFECTS THEIR SURVIVAL 
CCRL2 is present on the surface of immune cells, but also on endothelial cells. 
CCRL2 deficiency might therefore influence tumoral neoangiogenesis and as a 
consequence tumor cell survival and proliferation rate. We analyzed the 
proliferation and apoptosis of tumor cells by detecting specific markers by 
immunofluorescence. To analyze the tumor proliferation at early stages following 
grafting, we collected tumors from wild-type and CCRL2 knock-out mice at day 3 
and day 6 of tumor development. Cryosections of tumors were performed and the 
proliferation of tumor cells was determined by staining with an anti-Ki67 antibody. 
To quantify the proportion of proliferating cells, we analyzed the colocalization 
between Ki67 staining and Hoechst staining (Figure 4.9). No difference was 
observed between CCRL2+/+ and CCRL2-/- mice at day 3 and day 6 of tumor 
development.  
These results suggest that CCRL2 does not affect the proliferation of tumor 
cells. Proliferation of tumor cells increases the requirement for oxygen and 
nutrients provided by the vascularization. To identify apoptotic cells in tumors, 
CCRL2+/+ and CCRL2-/- mice were injected with 1.106 LLC. Ten days after tumor 
implantation, tumors were removed and we performed hematoxylin/eosin staining 
and immunofluorescence analyses of apoptotic and endothelial cells (Figure 4.10).   
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Figure 4.9. B16 tumors from CCRL2+/+ and CCRL2-/- mice display a similar 
proportion of proliferating cells. 1.106 B16 cells were injected subcutaneously in 
the back of CCRL2+/+ and CCRL2-/- mice. The mice were sacrificed at 3 and 6 
days, the tumors were recovered and embedded, without fixation, in OCT, and  
immunofluorescence staining was performed on tumor section. A. Proliferating 
cells were stained with an anti-Ki67 antibody (green) and the nuclei were stained 
with Hoechst 33342 (blue). Only tumors collected on day 6 are illustrated. 
Magnification 10x. B, C. Percentage of proliferating cells (Ki67+ Hoescht 33342+ 
cells) in tumors from CCRL2+/+ and CCRL2-/- mice at day 3 (B) and day 6 (C). The 
percentage of colocalization is calculated with the Jacop plugin of Image J 
software. This experiment was performed only once. 
 
Apoptotic cells and endothelial cells were identified by anti-cleaved caspase 3 
and anti-CD31 antibodies respectively. We observed a significant increase in the 
surface of necrotic areas and in the number of apoptotic cells at the periphery of 
these necrotic areas in tumors from CCRL2-/- mice. The staining by the anti-
cleaved caspase 3 antibody was indeed much more widespread as compared to 
CCRL2+/+ mice. These data seem to indicate that CCRL2 could affect the 
apoptosis and necrosis processes in the LLC tumor model. We could however not 
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conclude so far regarding potential differences in the number of blood vessels 
detected by the CD31 antibody.  
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Figure 4.10. In the absence of CCRL2, tumors present an increase in necrotic 
areas and apoptotic cells. LLC cells were injected subcutaneously in the back of 
CCRL2+/+ and CCRL2-/- mice. The mice were sacrificed 10 days later, and the 
tumors were removed and embedded, without fixation, in OCT. A. Representative 
views of HE staining (left panel) and CD31 and active caspase 3 immunostaining 
(right panel) for one of the 5 tumors from wild-type mice. B and C. Representative 
HE staining (B) and CD31 and active caspase 3 immunostaining (C) of one of the 5 
tumors from CCRL2 knock-out mice. The tumors were stained with an anti CD31 
antibidy coupled to PE and an anti-cleaved caspase 3 antibody detected by a 
secondary antibody coupled to FITC. Endothelial cells are therefore stained in red 
and apoptotic cells in green. Magnification x5 and x20 as indicated on the panels. 
These data are representative of 2 independent experiments. 
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4.6 THE EXPRESSION OF ANGIOGENIC AND INFLAMMATORY FACTORS IS 
MODIFIED IN CCRL2-DEFICIENT MICE 
Apoptotic and necrotic processes are closely linked to the tumor 
microvascularization. Indeed, the angiogenesis allows to support the supply of 
oxygen and nutrients necessary to tumor development. CCRL2 is expressed by 
endothelial cells, suggesting that this receptor might be important for the function of 
these cells and more precisely tumor neoangiogenesis (Gonzalvo-Feo et al., 
2014). Endothelial cells proliferate and migrate to the tumor site in response to the 
secretion of angiogenic factors by tumor cells, pro-tumoral immune cells or cells 
from the tumor microenvironment. To determine whether CCRL2 deficiency affects 
the neoangiogenic process supporting tumor survival and growth, we quantified the 
expression of several angiogenic and inflammatory factors in LLC tumors from 
CCRL2+/+ and CCRL2-/- mice. 1.106 LLC cells were injected in the flank mice, and 
the tumors were recovered ten days later. We extracted the RNA from the tumors, 
and by qPCR, analyzed the expression of angiogenic and inflammatory factors, 
including TSP1, TNFα, TGFβ, IFNγ, VEGFA, FGF2, MMP9, MMP10, CCL2, 
CXCL1, CXCL2, IL1β, IL-6 and IL-10. We observed that, in the absence of CCRL2, 
the expression of TSP1, VEGFA and FGF2 was increased as compared to control 
mice (Figure 4.11).  Others factors were altered in the absence of CCRL2, such as 
MMP9, TNF and IL-6, but these results were not confirmed in a second 
experiment and it will be necessary to perform additional repeats of this protocol a 
different time points of tumor development, in order to concluded regarding the 
whole set of markers that was tested so far. These preliminary data suggest 
however that CCRL2 might have a significant influence on the control of tumoral 
angiogenesis, by modulating the expression of angiogenic factors. 
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Figure 4.11 CCRL2 invalidation affects the expression of thrombospondin-1, 
VEGFA and FGF2 in LLC tumors. LLC tumors from CCRL2+/+ and CCLR2-/- 
mice, at day 10 of development, were recovered and digested. RNA was extracted, 
and qPCR was performed. The gene expression levels are relative to thje 
reference housekeeping gene GAPDH. This data set is representative of 2 
independent experiments. * and ** represent p values of < 0.05 and < 0.01 
respectively, ND = not detected.  
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5. DISCUSSION  
Several studies showed a correlation between the chemerin concentration in 
plasma or chemerin expression by tumors and the prognosis of human cancers, 
suggesting a role of chemerin in the physiopathology of cancer (Wang et al., 2014) 
(Pachynski et al, 2012). Our work has as main objective to understand the role of 
chemerin receptors in tumor development. First, we want to determine which 
receptor is involved in the control of tumor initiation and progression. To answer 
this question, we used genetically invalidated mice for each receptor and wild-type 
mice as controls, and these mice were injected with two syngeneic tumor cell  
lines, the B16 melanoma and Lewis lung carcinoma lines. 
It is known that ChemR23, the main chemerin receptor, is implicated in the 
migration of immune cells in response to chemerin, and the chemerin-ChemR23 
system is involved in various inflammatory diseases (Luangsay et al., 2009). Our 
results show however that ChemR23 does not affect tumor growth in our 
experimental models, neither the immune cell recruitment to the tumor site. 
ChemR23 does not seem therefore to play a significant role in the growth of 
established tumor cells. It remains possible however that ChemR23 is involved in 
the early steps of tumor initiation, such as in the chronic inflammatory processes 
that predispose to tumor development.  
CCRL2 is described as a non-functional receptor, because chemerin binding 
does not result in the activation of signaling cascades nor in receptor 
internalization. A recent study showed that this receptor allows dendritic cell 
migration to lymph nodes in a model of ovalbumin-induced airway inflammation 
(Otero et al., 2010). It was also proposed that CCRL2 acts by concentrating 
chemerin at the cell surface and presenting the ligand to ChemR23-expressing 
cells (Zabel et al., 2008). 
When we analyzed the growth of tumoral cell lines in CCRL2-deficient mice, we 
observed a reduction of tumor size, as compared to wild-type mice, suggesting a 
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pro-tumoral effect of CCRL2. This effect cannot be explained by a default of 
immune recruitment neither by an alteration of plasmatic chemerin levels. These 
results suggest that the role of CCRL2 is not related to changes in the efficiency of 
immune cell recruitment to the tumor in response to chemerin.  
In order to further test the relative roles of CCRL2 and ChemR23 in a tumor 
context, we suggest the generation of mice deficient for both ChemR23 and 
CCRL2. It is indeed still possible that the absence of CCRL2 modifies the local 
concentrations or the presentation of bioactive chemerin without affecting the 
circulating levels, and that the final outcome on tumor growth does involve 
ChemR23. Testing tumor growth and immune cell recruitment in mice invalidated 
for both receptors would allow to test this hypothesis. If deficient mice for the two 
receptors develop tumors similarly to CCRL2-deficient mice, it would confirm that 
ChemR23 is not involved in the phenotype of these mice. 
Tumor microenvironment is critical for the survival of tumor cells. 
Neovascularization of tumor enables tumor cell proliferation by supporting the 
supply of oxygen and nutrients, thereby avoiding apoptosis and necrosis of tumor 
cells. CCRL2 is known to be expressed by endothelial cells. Thus, we were 
interested to understand the potential role of CCRL2 on tumor cell proliferation and 
survival and the neoangiogenesis process. Our results show that the proliferation 
of tumor cells is not affected by the absence of CCRL2, suggesting that CCRL2 is 
not fundamental to the direct control of tumor growth. In CCRL2-deficient mice, an 
increase in the number of apoptotic cells and in the size of necrotic regions was 
however observed in the tumors, suggesting that CCRL2 affects tumor cell 
survival. Increase cell death by apoptosis and necrosis can be the result of 
insufficient oxygen supply, resulting from a relative defect in angiogenesis. We 
stained endothelial cells in tumor sections by using anti-CD31 antibodies, but could 
not detect significant differences in the density of blood vessels. However, the size 
of the tumors was quite different between CCRL2-invalidated mice and their 
controls, and the interpretation of blood vessel density is therefore difficult. To 
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better understand the cause of apoptotic and necrotic processes in CCRL2 KO 
mice, we suggest the staining of hypoxic regions in tumors with pimonidazole. This 
marker is able to bind to thiol-containing proteins when the oxygen concentration in 
the microenvironment is low.  
In order to understand if increased apoptosis in the absence of CCRL2 may be 
the result of poor vascularization, we observed the expression of several 
angiogenic factors in tumors. The results show an increase of TSP-1, VEGFA and 
FGF2 transcripts in the absence of CCRL2. Thrombospondin-1 is a matrix 
glycoprotein expressed by endothelial cells, adipocytes, smooth muscle cells, 
fibroblasts, monocytes and macrophages. It regulates the structure of the 
extracellular matrix, extracellular proteases and levels of active TGF-, resulting in 
an inhibition of tumor growth (Lawler, 2002) (Lopez-Dee et al., 2011). TSP1 is 
considered as a regulator of angiogenesis with direct and indirect effects. TSP1 
affects angiogenesis indirectly by activation of TGF-, which induces the apoptosis 
of endothelial cells. TSP1 can also directly inhibit the migration of endothelial cells 
and induce their apoptosis, through interaction with its receptor CD36. This 
interaction can inhibit survival pathways promoted by VEGF and FGF2 (Lawler, 
2002). 
Knowing that CCRL2 and TSP1 are both expressed by endothelial cells, we 
propose the hypothesis that CCRL2 would negatively regulate the expression of 
TSP1. To test this hypothesis, it will be necessary to test the expression of TSP1 at 
different time points during tumor development and in control conditions. 
The increased expression of VEGFA and FGF2 in the absence of CCRL2 could 
be explained by different mechanisms. The two genes might be downregulated 
directly or indirectly by CCRL2, but the increased expression of VEGFA and FGF2 
in tumors of CCRL2-/- mice is not really compatible with inefficient angiogenesis 
leading to tumor cell apoptosis and necrosis. Alternatively, this increased 
expression might rather be the consequence of hypoxia, and therefore secondary 
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to the increased expression of TSP1 and the angiogenesis defect in CCRL2-/- mice. 
This is the hypothesis we favor at present. To prove this hypothesis, it will be 
important to analyze the relative expression of the three angiogenesis regulators all 
along the development of tumors in order to determine which factor is modified 
first. It would also be interesting to test the expression of the receptors of VEGFA  
(VEGFR1 and VEGFR2) and FGF2 (FGFR1 and FGFR2) to test whether the 
increase in the two growth factors might be inefficient as a result of receptor 
downmodulation.  
The migration of endothelial cells can be a result of three different processes: 
chemotaxis, haptotaxis or mechanotaxis. The chemotaxis consists in the 
directional migration in response to a gradient of soluble chemoattractants. The 
main factors involved in chemotaxis of endothelial cells are VEGF, bFGF and 
angiopoietins, and the minor factors are FGF2, TGF-, interleukins and TNF- 
(Lamalice et al., 2007). We propose the hypothesis that CCRL2 can influence the 
chemotaxis of endothelial cells. If CCRL2 is absent, the endothelial cells might 
migrate less efficiently to the center of the tumor, in response to VEFGA and 
FGF2. As a result of defective angiogenesis, the local concentration of these two 
growth factors would increase further, while necrosis and apoptosis would be 
favored in the tumor. To understand further the potential defect in tumor 
angiogenesis in the absence of CCRL2, we suggest to complement the CD31 
labeling we performed by the immunofluorescence staining of blood vessels with a 
lectin coupled to FITC. Intraperitoneal injection of lectin-FITC in mice allows 
visualizing the tumor microvasculature with great details by fluorescence 
microscopy on tumors collected an hour later.  
It will also be important to test the role of CCRL2 in non tumoral angiogenesis. 
For this purpose, we propose to investigate the angiogenic response to VEGF in a 
model such as the mouse cornea micropocket angiogenesis assay, or similar 
assays that are perfomed in the back skin of mice, and compare CCRL2-/- and  
wild-type mice.   
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6. CONCLUSION 
In this work, we have shown that ChemR23, the major chemerin receptor, 
does not affect the tumor growth or the leukocyte recruitment, suggesting that this 
receptor is not implicated in the antitumoral effects of chemerin observed in the 
B16 and LLC tumor models. In contrast, CCRL2, a non-functional chemerin 
receptor, display a pro-tumoral effect in the same experimental models. This effect 
is presumably due to the fact that CCRL2 appears as a positive regulator of 
angiogenesis, with a potential implication of thrombospondin 1, or implicated in the 
migration of endothelial cells. As a result of improved supply of oxygen and 
nutrients, CCRL2 would protect tumor cells from necrosis and apoptosis.  
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